[HTML][HTML] Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers
Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia,
which often causes serious adverse drug reactions. Currently, there are no clinical …
which often causes serious adverse drug reactions. Currently, there are no clinical …
The pharmacogenetics of treatment with olanzapine
P Zubiaur, P Soria-Chacartegui… - …, 2021 - Taylor & Francis
Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is
associated with alterations in safety and efficacy. The aim of this systematic review is to …
associated with alterations in safety and efficacy. The aim of this systematic review is to …
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects
T Cabaleiro, R López‐Rodríguez… - Human …, 2013 - Wiley Online Library
Objective The pharmacokinetics of olanzapine and response to treatment could be affected
by polymorphisms in genes coding for drug‐metabolizing enzymes, transporters, or …
by polymorphisms in genes coding for drug‐metabolizing enzymes, transporters, or …
Pharmacogenetics of olanzapine metabolism
MM Söderberg, ML Dahl - Pharmacogenomics, 2013 - Taylor & Francis
The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual
variation leading to multiple-fold differences in drug exposure between patients at a given …
variation leading to multiple-fold differences in drug exposure between patients at a given …
CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients
Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients
with schizophrenia and bipolar disorders. Previous in vitro studies using human liver …
with schizophrenia and bipolar disorders. Previous in vitro studies using human liver …
Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure
Objective Metabolism of the atypical antipsychotic olanzapine (OLA) is partially catalyzed by
cytochrome P450 (CYP) 1A2, a target of aryl hydrocarbon receptor (AHR)-mediated …
cytochrome P450 (CYP) 1A2, a target of aryl hydrocarbon receptor (AHR)-mediated …
CYP1A2* 1D and* 1F polymorphisms have a significant impact on olanzapine serum concentrations
F Czerwensky, S Leucht, W Steimer - Therapeutic drug monitoring, 2015 - journals.lww.com
Background: Although several polymorphisms in olanzapine-metabolizing enzymes have
been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of …
been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of …
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance
KL Bigos, RR Bies, BG Pollock, JJ Lowy, F Zhang… - Molecular …, 2011 - nature.com
The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine,
has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a …
has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a …
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes
S Hägg, O Spigset, H Lakso, R Dahlqvist - European journal of clinical …, 2001 - Springer
Objective: Limited data suggest that CYP1A2 and CYP2D6 are involved in the metabolism of
olanzapine. The purpose of this study was to further elucidate the role of these enzymes in …
olanzapine. The purpose of this study was to further elucidate the role of these enzymes in …
[HTML][HTML] Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy
L Cong, Z Wan, P Li, D Liu, J He, Z An, L Liu - European Journal of …, 2022 - Elsevier
Clinical use of the a olanzapine has significantly different individual-to-individual outcomes.
Accordingly, this study aimed to develop a means of predicting response to olanzapine …
Accordingly, this study aimed to develop a means of predicting response to olanzapine …